Your fast track to the ultramodern lab

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate.

Your fast track to the ultramodern lab

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate.
Arrow Right

World-leading cancer diagnostics for everyone

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate.

World-leading cancer diagnostics for everyone

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI-supported workflow to optimize quality and response times, initially within prostate.
Meet the future of pathology
Arrow Right

How can an ultramodern laboratory, 100% specialized in uropathology, benefit you and your patients?

Your patient, our priority
Urologidagarna i Malmö, booth #43
Malmö Live
October 5–7, 2022 

Learn more about Inify Laboratories

Watch the video presentation

CUSTOMER CASE | Capio Urosurgical Center
“We had issues with long lead times for receiving results to our prostate biopsies. Inify delivers a solution where we get results within 5 working days. That was the main reason we started sending our samples to them”.
Martin Bergman
Consultant Urologist, CEO and founder
Capio Urosurgical Center

One out of seven will be diagnosed with prostate cancer

Handling of prostate biopsies makes up an increasing amount of workload for today’s pathology labs. Here, powerful decision support tools – such as Inify Prostate – have the potential to save valuable time for the pathologist, while ensuring a more objective, consistent and accurate evaluation of the biopsies.
For more panel discussions, please visit our YouTube channel
PANEL TALK 

Over 1,000 patients diagnosed: Panel talk Q2 report 2024

Inify reports sales of SEK 3.6 million in the quarter – up 62% compared to Q1. By the end of June, the laboratory had been open for over a year and had diagnosed more than 1,000 patients. More details about the laboratory operations and its success factors are discussed in a panel talk led by Ole Eikeland with Inify’s CEO Fredrik Palm and Laboratory Director Emelie Edvigsson. 
PANEL TALK 

Establishment in the UK and expansion in diagnostics: Panel talk Q3 report 2024

Inify has decided to establish its operations in the United Kingdom and to expand diagnostics into the gastrointestinal field. "The national health care system NHS in the UK has a high focus on pathways for patients that are going through cancer investigations, and here is exactly where we provide unique value" says Inify´s CEO Fredrik Palm. Listen to the panel talk led by Ole Eikeland with CEO Fredrik Palm for more details.

For more panel discussions, please visit our YouTube channel

Follow our YouTube channel

Newsletter

Want to join us on our journey?
Let’s talk.